Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MSLN-targeted CAR-T cells in Mesothelioma
NCT04577326Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2020
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M28z1XXPD1DNR in malignant pleural mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Sep 2020; status: active, not recruiting.
02
Drugs
M28z1XXPD1DNR
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04577326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577326.